[co-author: Jamie Dohopolski]
Love it or hate it, ignore the USPTO Patent Trial and Appeal Board (PTAB) at your peril. The introduction of the PTAB as part of the America Invents Act over ten years ago has forever changed...more
3/7/2022
/ §315(e) ,
35 U.S.C. § 285 ,
America Invents Act ,
Attorney's Fees ,
Biologics ,
Biosimilars ,
Biotechnology ,
Chemical Compounds ,
Claim Construction ,
Collateral Estoppel ,
Constitutional Challenges ,
Corporate Counsel ,
Credibility ,
Declaration ,
Depositions ,
Enhanced Damages ,
Estoppel ,
Evidence ,
Ex Partes Reexamination ,
Exceptional Case ,
Expert Testimony ,
Expert Witness ,
Final Written Decisions ,
Hatch-Waxman ,
Injunctive Relief ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Inventors ,
Life Sciences ,
Motion to Amend ,
Obviousness ,
Orange Book ,
Parallel Proceedings ,
Patent Applications ,
Patent Cancellation ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Prosecution History ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Pre-AIA Patents ,
Printed Publications ,
Prior Art ,
Section 112 ,
Section 325(d) ,
Standard Essential Patents ,
Testimony ,
USPTO ,
USPTO Pilot Program ,
Vacated ,
Written Descriptions
[co-author: Jamie Dohopolski]
Last year, the continued global COVID-19 pandemic forced American courts to largely continue the procedures set in place in 2020. The U.S. Court of Appeals for the Federal Circuit was no...more
2/9/2022
/ § 314(d) ,
35 U.S.C. §315(e)(1) ,
Absolute Intervening Rights Doctrine ,
Abuse of Discretion ,
Administrative Patent Judges ,
Administrative Procedure Act ,
America Invents Act ,
Appeals ,
Appointments Clause ,
Arbitrary and Capricious ,
Article of Manufacture ,
Assignor Estoppel ,
Burden of Proof ,
Claim Construction ,
Collateral Estoppel ,
Commercial Success ,
Confidential Information ,
Constitutional Challenges ,
Demand Letter ,
Denial of Institution ,
Design Patent ,
Director of the USPTO ,
Dismissals ,
Doctrine of Prosecution Disclaimer ,
Due Process ,
Equitable Estoppel ,
Estoppel ,
Evidence ,
Ex Partes Reexamination ,
Executive Branch ,
Executive Powers ,
Federal Rules of Evidence ,
Final Written Decisions ,
Forum Selection ,
FRCP 52(c) ,
GATT ,
Inferior Officers ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Reexamination ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Intervening Acts ,
Inventions ,
Issue Preclusion ,
Judicial Review ,
Lack of Authority ,
Lack of Jurisdiction ,
Likelihood of Success ,
Minerva Surgical Inc. v Hologic Inc. ,
Motion for Summary Judgment ,
Motivation to Combine ,
Nexus ,
Non-Disclosure Agreement ,
Nonobvious ,
Obviousness ,
Ornamental Design ,
Parallel Proceedings ,
Patent Applications ,
Patent Filings ,
Patent Infringement ,
Patent Litigation ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Petition for Writ of Certiorari ,
Pharmaceutical Patents ,
Post-Grant Review ,
Pre-GATT ,
Preliminary Injunctions ,
Principle Officers ,
Printed Publications ,
Prior Art ,
Real Party in Interest ,
Remand ,
Reversal ,
Rule 36 ,
Scope of Review ,
SCOTUS ,
Section 325(d) ,
Sua Sponte ,
Substantial Evidence ,
Totality of Evidence ,
United States v Arthrex Inc ,
USPTO ,
Vacated ,
Writ of Mandamus
[co-author: Kathleen Wills]
Last year, the global COVID-19 pandemic created unprecedented challenges for American courts. By making several changes, however, the U.S. Court of Appeals for the Federal Circuit was able to...more
2/3/2021
/ Abbreviated New Drug Application (ANDA) ,
Adidas ,
Administrative Law Judge (ALJ) ,
Administrative Patent Judges ,
Administrative Proceedings ,
America Invents Act ,
Appeals ,
Appointments Clause ,
Certiorari ,
Claim Construction ,
Comcast ,
Constitutional Challenges ,
Corporate Counsel ,
Covenant Not to Sue ,
Denial of Certiorari ,
Dismissals ,
Due Process ,
Estoppel ,
Evidence ,
FanDuel ,
Final Written Decisions ,
Google ,
Hewlett-Packard ,
Hulu ,
Inter Partes Reexamination ,
International Trade Commission (ITC) ,
Judicial Review ,
Lack of Authority ,
Motion to Amend ,
Nike ,
Obviousness ,
Oral Argument ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
Precedential Opinion ,
Real Party in Interest ,
Section 337 ,
Subject Matter Jurisdiction ,
Thryv Inc v Click-To-Call Technologies LP ,
Time-Barred Claims ,
United States v Arthrex Inc ,
USPTO
The PTAB Strategies and Insights newsletter provides timely updates and insights into how best to handle proceedings at the USPTO. It is designed to increase return on investment for all stakeholders looking at the entire...more
In 2018, the U.S. Court of Appeals for the Federal Circuit docketed close to 600 appeals from the U.S. Patent and Trademark Office (USPTO). That is the second highest number since starting to hear post-American Invents Act...more
2/28/2019
/ § 315(b) ,
Adverse Judgments ,
Appeals ,
Article III ,
Assignor Estoppel ,
Burden of Proof ,
Burden-Shifting ,
Claim Construction ,
Collateral Estoppel ,
Corporate Counsel ,
Doctrine of Prosecution Disclaimer ,
Estoppel ,
Final Written Decisions ,
Injury-in-Fact ,
Inter Partes Review (IPR) Proceeding ,
Inventors ,
Non-Appealable Decisions ,
Non-Practicing Entities ,
Obviousness ,
Oil States Energy Services v Greene's Energy Group ,
Partial Institution ,
Patent Litigation ,
Patent Owner Preliminary Response ,
Patent Ownership ,
Patent Trial and Appeal Board ,
Patents ,
Precedential Opinion ,
Printed Publications ,
Prior Art ,
Private Property ,
Public Rights Doctrine ,
Real Party in Interest ,
Right to a Jury ,
Right To Appeal ,
SAS Institute Inc. v Iancu ,
Section 101 ,
Section 102 ,
Section 103 ,
Seventh Amendment ,
Sovereign Immunity ,
Standing ,
Time-Barred Claims
Eleven of thirteen cannabis patent claims survive PTAB challenge.
Insys Development Company, Inc. filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s patent directed to the use of...more
1/28/2019
/ Biopharmaceutical ,
Cannabidiol (CBD) oil ,
FDA Approval ,
Hemp ,
Inter Partes Review (IPR) Proceeding ,
Marijuana ,
Obviousness ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Pharmaceutical Patents ,
Prior Art
In 2016, the US Court of Appeals for the Federal Circuit docketed more appeals from the US Patent and Trademark Office (PTO) than any other venue—a first in its over 30-year history. The post grant proceedings created by the...more
3/19/2018
/ § 315(b) ,
Administrative Procedure ,
Administrative Procedure Act ,
America Invents Act ,
Anticipation ,
Appeals ,
Broadest Reasonable Interpretation Standard ,
Burden of Persuasion ,
Burden of Proof ,
Claim Amendments ,
Claim Construction ,
Due Process ,
Ex Partes Reexamination ,
Expert Testimony ,
Final Written Decisions ,
Incorporation by Reference ,
Inter Partes Review (IPR) Proceeding ,
Judicial Review ,
Non-Appealable Decisions ,
Notice Requirements ,
Obviousness ,
Patent Invalidity ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Preponderance of the Evidence ,
Prior Art ,
Reaffirmation ,
Remand ,
Reversal ,
Substantial Evidence Standard ,
Vacated
Is there a growing split in the Federal Circuit on the proper remedy where the Patent Trial and Appeal Board (“Board”) fails to carry its burden? The recent precedential decision of In re Hodges, __ F.3d __, 2018 WL 817248...more
2/27/2018
/ Anticipation ,
Appeals ,
Burden of Proof ,
Claim Construction ,
Obviousness ,
Patent Applications ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Prior Art ,
Remand ,
Remedies ,
Reversal ,
Substantial Evidence
While petitioners are successful over 60% of the time in getting the PTAB to institute trial on patents in the biotech, chemical, electrical/computer, mechanical, and business method arts, that is not the case for design...more
As of January 2017, the institution rate for Patent Trial and Appeal Board trials involving design patents was 37 percent. That is significantly lower than every other technology area and makes design patents the only...more
5/25/2017
/ Biotechnology ,
Design Patent ,
Obviousness ,
Patent Examinations ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Prior Art ,
Priority Patent Claims ,
USPTO
On November 3, 2015, the Federal Circuit issued Belden Inc. v. Berk-Tek LLC1, a rare precedential opinion reversing a determination by the Patent Trial and Appeal Board (PTAB) in an inter partes review proceeding. This is...more